Does 80% of people with IBS have SIBO? Where that number comes from

Where the “80%” comes from

In 2000, Mark Pimentel, Erica Chow and Huang Lin published a study in The American Journal of Gastroenterology titled “Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome.” It looked at 202 adults who met the Rome I criteria for IBS and had been referred from the community for a lactulose hydrogen breath test. Of those 202, 157 — 78% — had a positive test, which the authors interpreted as small intestinal bacterial overgrowth.

The study did more than count. Patients with a positive test were treated with antibiotics, and those who returned for a repeat breath test were checked for eradication. Of the 47 who did, 25 had their overgrowth eradicated — and those who eradicated reported more symptom relief than those who did not. That link between eradication and relief is what made the study influential, and the 78% figure is what made it famous.

Why 78% cannot simply be repeated as “80% of IBS”

The figure is real, but it answers a narrower question than it is usually asked to answer. Four things limit how far it travels:

• Who was measured. These were people referred by their doctor for a specific overgrowth test, not a random sample of everyone living with IBS. People referred for testing tend to have more severe, longer-standing or treatment-resistant complaints than the average person with IBS.
• Which test was used. Lactulose is a sugar humans cannot digest; it keeps travelling until bacteria or other microbes break it down. A breath hydrogen rise can therefore come from overgrowth in the small intestine, but also from fast transit or simply from normal fermentation in the colon. The test is sensitive, not specific.
• Which cut-off counted as positive. Change the threshold that defines a positive result and the percentage moves — sometimes a lot. Meta-analyses report this explicitly as “significant heterogeneity between studies”.
• Which era. This was Rome I, before Rome II, III and IV refined how IBS is defined. Methane producers were not measured as a separate finding (we now speak of IMO), and hydrogen sulfide (ISO) was not on the radar at all.

What the research that followed found

The same question — how common is SIBO in IBS? — has since been asked hundreds of times, with answers that range from a few percent to almost four in five. The table below shows four reference points, chosen because each uses a different method.

Read together, these studies say something more honest than “80%”: roughly one third to one half of people with IBS test positive when a breath test is used, and far fewer when bacteria are cultured directly from the small intestine. Ford and colleagues (2009) found just 4% of IBS patients positive by jejunal aspirate culture — the same share as in healthy controls. Posserud and colleagues (2007) reported the same 4% in both groups, while still finding mildly raised bacterial counts more often in IBS (43% vs 12%).

What is consistent across all of it

• The contrast with healthy people is the strongest signal. Chen and colleagues (2018) pooled 50 studies and found IBS patients were about four to five times more likely to test positive than controls (OR 4.7, 95% CI 3.1–7.2) — even though the absolute percentage was 38%, not 80%.
• The method changes the answer more than the population does. 40% in breath-test studies versus 19% in culture studies (Chen 2018), 54% versus 4% (Ford 2009). There is still no agreed gold standard for SIBO, which is the real open question in this literature.
• Some groups test positive more often. Female sex, older age and diarrhoea-predominant IBS were each associated with higher odds of SIBO in the Chen meta-analysis; proton pump inhibitor use was not.
• Motility appears in every account. Posserud found signs of altered small-bowel motility in 86% of the IBS patients with SIBO versus 39% of those without — a reminder that what keeps an overgrowth in place is often the cleaning rhythm of the gut itself.

So is the “80%” claim wrong?

Not wrong — out of context. It is a real finding from a real study, in a specific group of people, using a specific test with a specific cut-off. Used as a headline (“8 out of 10 people with IBS have SIBO”), it becomes an argument nobody can check. The defensible version is quieter: a substantial minority of people with IBS carry an overgrowth, they are several times more likely to do so than healthy people, and the only way to know whether you are one of them is to be tested.

What this means for you

• If your symptoms have been labelled “just IBS” and nothing is changing, asking whether SIBO or IMO has been ruled out is a reasonable question, not an alternative-medicine one.
• Ask which test was used and which criteria defined a positive result. A percentage without that context is a slogan.
• A positive breath test does not prove cause, and a negative one does not exclude an overgrowth — the tests are imperfect and thresholds are debatable.
• The pattern matters more than a yes/no. Hydrogen-dominant SIBO, methane overgrowth (IMO) and hydrogen sulfide production (ISO) look different in the symptoms they cause and are approached differently.
• Testing and interpretation are a support step. Diagnosis, medication and prescriptions always remain with your physician.

This article is for general information and does not replace medical advice. Medical decisions, medication and prescriptions always remain with your physician.